UOC
TXMD icon

UBS O'Connor’s TherapeuticsMD TXMD Stock Holding History

UBS O'Connor’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,000
Closed -$1.65M – 513
2016
Q1 		$1.28M Buy
4,000
+3,750
+1,500% +$1.28M 0.02% 302
2015
Q4 		$130K Sell
250
-504
-67% -$186K ﹤0.01% 392
2015
Q3 		$221K Sell
754
-5,066
-87% -$1.8M ﹤0.01% 449
2015
Q2 		$2.29M Buy
5,820
+983
+20% +$347K 0.04% 320
2015
Q1 		$1.46M Sell
4,837
-163
-3% -$39.8K 0.03% 334
2014
Q4 		$1.11M Buy
5,000
+500
+11% +$103K 0.02% 347
2014
Q3 		$1.04M Hold
4,500
– – 0.02% 340
2014
Q2 		$994K Sell
4,500
-500
-10% -$111K 0.01% 331
2014
Q1 		$1.58M Buy
+5,000
New +$1.59M 0.03% 299
2013
Q4 		– Sell
-2,000
Closed -$293K – 497
2013
Q3 		$293K Buy
+2,000
New +$242K 0.01% 346

Other funds holding TXMD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

UBS O'Connor's TXMD Position: Q2 2016 in Review

UBS O'Connor sold out of TherapeuticsMD (TXMD) in Q2 2016, closing a stake of 4,000 shares — an estimated $1.65M sold.

UBS O'Connor first reported a position in TXMD in Q3 2013 and held it in 10 quarters. The position peaked at $2.29M in Q2 2015. 123 funds tracked by Wall St. Rank hold TXMD as of Q2 2016.

  • UBS O'Connor reported no remaining TherapeuticsMD position as of Q2 2016 after selling out during the quarter.
  • UBS O'Connor sold 4,000 TherapeuticsMD shares in Q2 2016, an estimated $1.65M.
  • UBS O'Connor first reported a position in TherapeuticsMD in Q3 2013 and held it in 10 quarters.
  • UBS O'Connor's TherapeuticsMD position peaked at $2.29M in Q2 2015.
  • 123 funds tracked by Wall St. Rank held TherapeuticsMD as of Q2 2016.

Based on UBS O'Connor's 13F filing for Q2 2016, filed 12 Aug 2016.